Johnston John Joseph 4

What Happened

• John J. Johnston, a director of MaxCyte, was granted a total of 80,000 restricted stock units (RSUs) on June 17, 2026. The filing shows two grant lines: 30,421 shares and 49,579 shares (the second listed as a derivative), each with an acquisition price of $0.00 (total cash outlay $0).
• This was an award/compensation grant (transaction code A), not an open‑market purchase or sale. Such grants are routine director compensation rather than immediate market trades.

Key Details

• Transaction date: June 17, 2026; Form 4 filed June 22, 2026 (filed five days after the grant date).
• Price: $0.00 per RSU; total RSUs granted: 80,000.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: F1 — these are RSUs; each RSU is a contingent right to one share. F2 — this is the issuer’s annual grant under the Equity Grant Policy for non‑employee directors; underlying shares vest on June 17, 2027, contingent on continuous service.
• Timeliness: The Form 4 was filed five days after the grant; Form 4s are generally required within two business days, so this appears to be a late filing (may warrant monitoring for future timeliness).

Context

• RSUs are derivative awards that convert to common shares only if vesting conditions are met (here, one year of continuous service). They do not represent immediate share ownership or a cash investment by the insider.
• Non‑employee director compensation grants are common and typically intended for retention and alignment with shareholders; they should be interpreted as routine compensation rather than a direct buy/sell signal.